Literature DB >> 17375909

Platinum complex as a nanomolar protein kinase inhibitor.

Douglas S Williams1, Patrick J Carroll, Eric Meggers.   

Abstract

A pyridocarbazole platinum complex, which matches the overall shape of the natural product staurosporine, binds with high affinity at the adenosine triphosphate binding site of glycogen synthase kinase 3 (GSK-3alpha).

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17375909     DOI： 10.1021/ic062055t

Source DB:  PubMed          Journal:  Inorg Chem        ISSN： 0020-1669            Impact factor:   5.165


  10 in total

1.  Conformational landscape of platinum(II)-tetraamine complexes: DFT and NBO studies.

Authors:  Austin B Yongye; Marc A Giulianotti; Adel Nefzi; Richard A Houghten; Karina Martínez-Mayorga
Journal:  J Comput Aided Mol Des       Date:  2010-03-24       Impact factor: 3.686

2.  Organometallic Pyridylnaphthalimide Complexes as Protein Kinase Inhibitors.

Authors:  Sebastian Blanck; Thomas Cruchter; Adina Vultur; Radostan Riedel; Klaus Harms; Meenhard Herlyn; Eric Meggers
Journal:  Organometallics       Date:  2011-07-18       Impact factor: 3.876

3.  Bioactive cyclometalated phthalimides: design, synthesis and kinase inhibition.

Authors:  Sebastian Blanck; Yann Geisselbrecht; Katja Kräling; Stephen Middel; Thomas Mietke; Klaus Harms; Lars-Oliver Essen; Eric Meggers
Journal:  Dalton Trans       Date:  2012-06-26       Impact factor: 4.390

4.  Cisplatin inhibits protein splicing, suggesting inteins as therapeutic targets in mycobacteria.

Authors:  Liyun Zhang; Yuchuan Zheng; Brian Callahan; Marlene Belfort; Yangzhong Liu
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

5.  The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.

Authors:  Peng Xie; Craig Streu; Jie Qin; Howard Bregman; Nicholas Pagano; Eric Meggers; Ronen Marmorstein
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

6.  Toward the development of a potent and selective organoruthenium mammalian sterile 20 kinase inhibitor.

Authors:  Ruchi Anand; Jasna Maksimoska; Nicholas Pagano; Eric Y Wong; Phyllis A Gimotty; Scott L Diamond; Eric Meggers; Ronen Marmorstein
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

7.  Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.

Authors:  Peng Xie; Douglas S Williams; G Ekin Atilla-Gokcumen; Leslie Milk; Min Xiao; Keiran S M Smalley; Meenhard Herlyn; Eric Meggers; Ronen Marmorstein
Journal:  ACS Chem Biol       Date:  2008-05-16       Impact factor: 5.100

Review 8.  Organometallic anticancer compounds.

Authors:  Gilles Gasser; Ingo Ott; Nils Metzler-Nolte
Journal:  J Med Chem       Date:  2010-11-15       Impact factor: 7.446

9.  Inhibition of mitogen-activated protein kinase (MAPK) and cyclin-dependent kinase 2 (Cdk2) by platinum(II) phenanthroline complexes.

Authors:  Emma S Child; Savvas N Georgiades; Kirsten N Rose; Verity S Stafford; Chirag B K Patel; Joachim H G Steinke; David J Mann; Ramon Vilar
Journal:  J Chem Biol       Date:  2011-02-26

10.  Non-ATP-Mimetic Organometallic Protein Kinase Inhibitor.

Authors:  Kathrin Wähler; Katja Kräling; Holger Steuber; Eric Meggers
Journal:  ChemistryOpen       Date:  2013-09-05       Impact factor: 2.911
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.